Table 4.
Reduction in the duration of herpes zoster-associated pain medication use in participants with confirmed herpes zoster.
| Study | RZV | Placebo | VE (%) | 95% CI | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | n | T (d) | Tmean (range) | N | n | T (d) | Tmean (range) | ||||
| ZOE-50 | 9 | 6 | 159 | 26.0 (55) | 254 | 190 | 14,524 | 76.1 (1265) | 24.7 | (−73.7, 67.4) | 0.506 |
| ZOE-70 | 23 | 10 | 1108 | 109.5 (654) | 223 | 160 | 31,949 | 199.3 (4528) | 49.3 | (2.9, 73.5) | 0.040 |
| ZOE-HSCT* | 49 | 32 | 1917 | 59.4 (435) | 135 | 94 | 15,465 | 164.1 (1641) | 22.5 | (−15.9, 48.1) | 0.214 |
This analysis excluded pain medication linked to a confirmed HZ case after relapse of the pre-existing malignant disease.
CI, confidence interval; HSCT, hematopoietic stem cell transplantation; HZ, herpes zoster; N, number of participants with at least 1 confirmed HZ episode; n, number of participants with at least 1 confirmed HZ episode and at least 1 d of HZ-associated pain medication use; RZV, recombinant zoster vaccine; T, sum of follow-up period (for participants without pain medication, T is 1; for participants with pain medication, T is the duration of pain medication) expressed in d; Tmean (range), mean and range (minimum subtracted from maximum value for a given participant group) of the duration (in d) of HZ-associated pain medication use; VE, vaccine efficacy (adjusted by age strata and region in the ZOE-50 and ZOE-70 studies); ZOE, Zoster Efficacy Study.